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ABSTRACT
Survival for lung cancer patients remains dismal and is largely attributed to 
treatment resistance. To identify novel target genes the modulation of which could 
modify platinum resistance, we performed a high-throughput RNAi screen and 
identified Yes-associated protein (YAP1), a transcription coactivator and a known 
oncogene, as a potential actionable candidate. YAP1 ablation significantly improved 
sensitivities not only to cisplatin but also to ionizing radiation, both of which are DNA-
damaging interventions, in non-small cell lung cancer (NSCLC) cells. Overall YAP1 was 
expressed in 75% of NSCLC specimens, whereas nuclear YAP1 which is the active form 
was present in 45% of 124 resected NSCLC. Interestingly, EGFR-mutated or KRAS-
mutated NSCLC were associated with higher nuclear YAP1 staining in comparison 
to EGFR/KRAS wild-type. Relevantly, YAP1 downregulation improved sensitivity to 
erlotinib, an EGFR inhibitor. A pharmacological inhibitor of YAP1 signaling, verteporfin 
also synergized with cisplatin, radiation and erlotinib in NSCLC cells by potentiating 
cisplatin and radiation-related double-stranded breaks and decreasing expression of 
YAP1 and EGFR. Taken together, our study is the first to indicate the potential role 
of YAP1 as a common modulator of resistance mechanisms and a potential novel, 
actionable target that can improve responses to platinum, radiation and EGFR-
targeted therapy in lung cancer.
INTRODUCTION
Lung cancer is the leading cause of cancer-related 
deaths worldwide. The mainstay of treatment for most 
patients with advanced lung cancer remains platinum-
based chemotherapy, while radiation plays a key role in 
the treatment of locally-advanced disease, many times 
given concurrently with platinum-based chemotherapy. 
Despite recent treatment advances, primary and acquired 
resistance to chemotherapy and radiation therapy still leads 
to a dismal survival, around 16% at 5 year [1]. Platinum 
compounds function by forming platinum-DNA adducts 
and subsequently damaging DNA and thereby leading 
to cell death. Platinum-induced DNA damage is mainly 
repaired by the nucleotide excision repair pathway (NER) 
[2, 3]. The ERCC1 (excision repair cross-complementation 
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group 1) protein, a key component of NER, has been 
implicated to be an important factor in platinum resistance 
[2, 3]. However, even in ERCC1-low tumors, only half of 
the patients respond to platinum therapy and all tumors 
ultimately develop resistance over time. This suggests 
accordingly that the resistance mechanisms to platinum 
may be multifactorial and likely multiple elements remain 
to be further elucidated. Radiation causes DNA damage 
and cell death via the generation of free radicals. Enhanced 
DNA repair or damage tolerance have been implicated in 
radiation resistance [4]. Besides ERCC1, other factors 
involved in DNA repair pathways, such as BRCA1, 
BRCA2, and poly (ADP-ribose) polymerase (PARP) 
have also been implicated in platinum resistance [5–8]. 
Moreover, further epigenetic and genetic alterations, such 
as changes in BCL-2 family members and caspases, 
have been linked to regulation of platinum responses [6]. 
Nevertheless, there are no clinically proven biomarkers 
for either platinum or radiation response. On the other 
hand, clinical outcomes in subgroups of lung cancer 
patients have been improved by identifying and targeting 
key oncogenic driver mutations, such as activating EGFR 
mutations [9]. Nearly all tumors progress over time due to 
acquired drug-resistance to EGFR-targeted therapy [9–13] 
and two of the major molecular mechanisms of such 
resistance include secondary EGFR T790M mutations 
and MET amplification [9]. Nevertheless, the resistance 
mechanisms to anti-EGFR treatment remain unknown 
in about one third of the cases. Taken together, there is a 
definite need to identify predictive biomarkers for these 
commonly used modalities as well as to develop novel 
synergistic therapies based on better understanding of 
biology in order to improve on our current treatment 
paradigms in lung cancer. 
To address these needs, we have completed a 
high-throughput RNAi screen to identify, in an unbiased 
fashion, modulating factors of platinum resistance and 
have identified YAP1, a transcription co-activator, as a 
novel actionable candidate to synergize with platinum 
therapy. Our studies further indicate that YAP1 may be a 
common modulator of resistance mechanisms to platinum, 
radiation and EGFR-targeted therapy. Both genetic and 
pharmacological YAP1 inhibition was associated with 
improved sensitivities to these treatment modalities in 
lung cancer cells. 
RESULTS
High-throughput RNAi screen for cisplatin 
resistance and synergistic partners
In order to understand the pathways that can 
synergize with cisplatin, we utilized a high-throughput 
RNAi platform to screen for novel target genes the 
modulation of which could influence drug sensitivity of 
lung cancer cells in response to platinum. The RNAi high-
throughput screen with the shRNA library used in our 
study has previously been applied in several cancer types 
and has led to the successful identification of multiple 
novel key targets [14, 15]. 
We first transfected lung cancer cells (PC9) with 
an shRNA viral library containing ~60,000 individual 
shRNAs targeting almost the entire human genome, and 
then identified depleted versus enriched shRNAs following 
two weeks of vehicle DMSO control vs. cisplatin 
treatment in surviving cells (Figure 1). We hypothesized 
that the shRNAs that were depleted more in cisplatin-
treated versus control cells might represent genes whose 
function is key for cell survival in the face of cisplatin-
induced damage. Thereby, inhibiting these genes could 
potentially synergize with cisplatin therapy. As previously 
published [14, 17, 18], we utilized a rigorous set of criteria 
and procedures for analyzing data, using the Bioconductor 
and Extraction of Differential Gene Expression libraries 
in R program. Standard quality control studies suggested 
excellent correlation between replicates. For instance, the 
Pearson correlation and Spearman correlation coefficients 
were 0.88 and 0.85 respectively for cisplatin triplicates. 
The genes from the initial positive “hits” screen were 
ranked as mentioned in the methods section. After using 
strict selection criteria, we selected a narrow list of 
highly depleted genes from the cisplatin screen, including 
Desmoglein 3 (−116 fold change), Aurora kinase A (−113 
fold change), and YAP1 (Yes associated protein) (−80 fold 
change) (Table 1). Moreover, a preliminary and limited 
validation study revealed that siRNA targeting above three 
genes effectively silenced their expression and improved 
cisplatin sensitivity (data not shown). 
YAP1 was identified as a potential candidate 
modulator of cisplatin resistance
Our preliminary validation study indicated that 
YAP1 may be a bona fide mediator of cisplatin sensitivity 
in lung cancer cells. YAP1 shRNAs were depleted 80 fold 
in the cisplatin screen. YAP1 was initially identified as a 
protein interacting with the non-receptor tyrosine kinase 
c-Yes [24] and is now considered as a nuclear effector 
of the Hippo pathway that promotes cell growth as a 
transcriptional co-activator [25]. Several lines of evidence 
suggested its role in predicting tumor progression and drug 
responses. For instance, overexpression of YAP1 could 
contribute to progression and poor prognosis of NSCLC 
[26], while knockdown of YAP1 sensitized ovarian 
cancer cells to cisplatin, erlotinib (EGFR Tyrosine kinase 
inhibitor) and S12 (survivin inhibitor) [27]. To further 
validate this promising target identified in our screen, we 
first confirmed that different shRNAs and an siRNA pool 
targeting YAP1 can efficiently knockdown YAP1 protein 
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expression in the PC9 lung cancer cell line (Figure 2A 
and 2B). Next, the effects of YAP1 knockdown on drug 
responses were examined. YAP1 knockdown by either 
shRNA (Figure 2C) or siRNA (Figure 2D) indeed quite 
prominently improved sensitivities to cisplatin in PC9 lung 
cancer cells in a synergistic manner (CI < 1). Moreover, 
YAP1 knockdown combined with platinum therapy also 
induced apoptosis as measured by induction of PARP 
cleavage (Figure 2B). Expression of YAP1 was examined 
in several NSCLC cell lines (Figure 3A). Combination 
experiments between YAP1 knockdown and cisplatin were 
further investigated in two other NSCLC cell lines with 
YAP1 expression, HCC827 and H157. Similar synergistic 
effects were observed (Figure 3C and 3D). Interestingly, 
YAP1 ablation by itself led to decreased colony formation 
in all three cell lines examined. Taken together, YAP1 
knockdown not only conferred a “single-agent” activity 
but also sensitized NSCLC cells to cisplatin. 
YAP1 inhibition sensitized lung cancer cells to 
radiation
Radiation treatment, like cisplatin, also causes 
DNA damage and can potentially share certain resistance 
mechanisms with cisplatin. Thus, we next examined the 
effects of knockdown of YAP1 on radiation sensitivities. 
As shown in Figure 4A and 4B, YAP1 knockdown 
synergized with radiation in PC9, HCC827 and H157 cells 
as determined by clonogenic assays (CI < 1, P < 0.05).
YAP1 expression in primary human NSCLC 
To determine the expression profile of YAP1 in 
primary lung tumors, we performed IHC with YAP1 
staining using tissue microarrays constructed from 124 
well-annotated NSCLC tumor tissues (derived from 
stage I to III non-small cell lung cancer specimens from 
Figure 1: Schema of RNAi screen for cisplatin. A pooled library of shRNA-mirs was introduced to lung cancer cells (PC9) at a 
multiplicity of infection of one (MOI = 1). Cells were treated for 14 days with control (DMSO vehicle) vs. cisplatin. Subsequently, genomic 
DNA was extracted, shRNAs were amplified, and deep sequencing was performed to determine the identities of shRNAs. 
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patients undergoing lung cancer resection between 2010 
and 2012). Positive cases were defined as samples with 
positive YAP1 staining (either cytoplasmic or nuclear 
YAP1 or both). YAP1 was noted to be expressed in 77% 
of tumors. About half of the tumor specimens stained 
positive for nuclear YAP1, which is the functionally 
active form of YAP1 (Table 2). The nuclear YAP1 staining 
was positive in 50% of lung adenocarcinoma, 59% of 
squamous cell carcinoma and 32% of large cell carcinoma, 
respectively. Interestingly, among cases where EGFR 
and KRAS mutation status were known (n = 76), there 
was a higher YAP1 nuclear staining in EGFR-mutated 
(n = 16, average H score = 47, positive nuclear YAP1 
in 63% of patients,) or KRAS-mutated (n = 23, average 
H score = 51, positive nuclear YAP1 in 65% of patients) 
lung adenocarcinoma in comparison to EGFR/KRAS 
wild type (n = 37, average H score = 19, positive nuclear 
YAP1 in 43% of patients) (P < 0.05) (Figure 5, Table 2). 
A potential link between YAP1 and EGFR-RAS mediated 
oncogenesis was implicated by a recent observation that 
activation of EGFR-RAS signaling activated YAP1 and 
subsequently promoted glial cell growth [28]. Another 
study also indicated a positive correlation between YAP1 
expression and EGFR mutations [29]. In concordance 
with these observations, our data suggest that EGFR/
KRAS driven signaling might activate YAP1 leading to 
its nuclear translocation in lung cancers. 
YAP1 inhibition sensitized lung cancer cells to 
erlotinib
Our IHC experiments indicated that EGFR-
mutated lung cancers were associated with higher YAP1 
activation, thus YAP1-targeted therapy may potentiate the 
Table 1: Top 20 primary screen hits in the cisplatin screen
Gene Symbol Description Fold Change P-value
Validated  
in 
preliminary 
screen
DHRS3 Dehydrogenase/reductase (SDR family) member 3 –151.74 7.33E-04
DIP2B DIP2 disco-interacting protein 2 homolog B –142.05 1.38E-04
HCN2, 
LOC100134399
Hyperpolarization-activated, cyclic nucleotide-gated K+ 2 –138.49 8.43E-04
RRP1 Recombination repair protein 1 –128.13 6.31E-04
PFKFB3 6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 3 –125.69 1.03E-03
DSG3 Desmoglein 3 –115.58 3.35E-04 Yes
AURKA, 
AURKAPS1
Aurora kinase A –112.96 5.27E-03 Yes
SMURF2 SMAD specific E3 ubiquitin protein ligase 2 –82.51 2.65E-04
JAKMIP3 Janus kinase and microtubule interacting protein 3 –81.4 5.28E-04
YAP1 Yes-associated protein 1 –81.18 1.54E-03 Yes
C6orf140
Or GLYATL3
GLYATL3 glycine-N-acyltransferase-like 3 –79.83 1.88E-03
SLC35E3 Solute carrier family 35, member E3 –79.1 4.19E-03
ATP1B2 ATPase, Na+/K+ transporting, beta 2 polypeptide –76.97 5.50E-04
CCDC9 Coiled-coil domain containing 9 –76.73 3.57E-04
CAT Catalase –73.97 3.01E-03
VARS2 Valyl-tRNA synthetase 2, mitochondrial –73.71 2.43E-04
LOC150577 Long intergenic non-protein coding RNA 1104 –72.77 1.25E-03
FAM159A Family with sequence similarity 159, member A –72.74 1.52E-03
OR10A3 Olfactory receptor, family 10, subfamily A, member 3 –72.36 1.35E-03
Fold change indicates relative fold depletion of shRNA primary screen hairpin hits in cisplatin vs. DMSO control
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Figure 2: (A) Western blotting: YAP1 shRNA #1, #2 and #3 were introduced to PC9 cells separately with different concentrations 
of doxycycline (Dox) induction. YAP1 shRNA#1 had the highest knockdown efficiency and was used in the subsequent experiments. 
(B) Western blotting: The effects of YAP1 siRNA transfection to PC9 cells. cPARP: cleaved PARP. Con: Vehicle DMSO control. 
Cis: 1 uM cisplatin. (C) Clonogenic assay: The effects of inducible shRNA #1-mediated YAP1 knockdown on cisplatin activities in 
PC9 cells. ∆ indicates that there was a synergistic effect between cisplatin and shRNA-mediated YAP1 knockdown (CI < 1). 
* = P < 0.05. –Dox: absence of doxycycline. + Dox: presence of 2 ug/ml doxycycline. (D) Clonogenic assay: The effects of siRNA-
mediated YAP1 knockdown on cisplatin responses in PC9 lung cancer cells. ∆ indicates that there was a synergistic effect between cisplatin 
and siRNA-mediated YAP1 knockdown (CI < 1). * = P < 0.05.
Figure 3: (A) Western blotting: Expression of YAP1 in NSCLC cell lines. NHBE: normal human bronchial epithelial cells. 
(B) Western blotting: The effects of YAP1 siRNA in HCC827 and H157 cells. Con: Vehicle DMSO control. Cis: 3uM cisplatin. (C) 
Clonogenic assay: The effects of siRNA-mediated YAP1 knockdown on cisplatin activities in HCC827 and H157 lung cancer cells. Control: 
Non-targeted siRNA. ∆ indicates that there was a synergistic effect between cisplatin and siRNA-mediated YAP1 knockdown (CI < 1). 
* = P < 0.05. 
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cytotoxicity of erlotinib (tyrosine kinase inhibitor targeting 
EGFR) in EGFR-mutated NSCLC cells. To test this 
possibility, we examined the effects of siRNA-mediated 
YAP1 knockdown on erlotinib cytotoxicity. As shown 
in Figure 5B and 5C, YAP1 blockage indeed synergized 
with erlotinib in both PC9 and HCC827 cells (CI < 1, 
P < 0.05). 
Verteporfin, a pharmacological inhibitor of 
YAP1, sensitized NSCLC cells to cisplatin, 
radiation and erlotinib
We further examined the effects of a 
pharmacological inhibitor of YAP1 signaling, verteporfin, 
on cytotoxicity of cisplatin, radiation and erlotinib. The 
association of YAP1 and TEAD transcription factor has 
been reported to be essential for YAP1-driven oncogenic 
growth. A recent study suggested that verteporfin could 
disrupt the active YAP1-TEAD complex and thereby leads 
to inhibition of YAP1-induced liver overgrowth [30]. 
Verteporfin is currently used in clinic for the treatment of 
neovascular macular degeneration. As shown in Figure 
6A, verteporfin indeed reduces phosphorylation of YAP1 
in PC9 lung cancer cells at baseline or in the presence 
of cisplatin, whereas a YES inhibitor, dasatinib had no 
such effects. Moreover, verteporfin treatment improved 
cisplatin cytotoxicity synergistically (Figure 6B, CI < 1, 
P < 0.05). Verteporfin also synergizes with radiation 
and erlotinib in PC9 lung cancer cells suggestive of a 
functional synergism upon YAP1 blockade (Figure 6B, 
CI < 1, P < 0.05). To gain insights into the underlying 
mechanisms of the synergism between verteporfin and 
cisplatin, we next investigated their effects on γ-H2AX, 
induction of which is considered as a marker for DNA 
double strand breaks (DSBs). As shown in Figure 6C, 
there were persistent and more pronounced γ-H2AX 
induction with combined verteporfin and cisplatin 
treatment than either agent alone, especially at 48 hours. 
Similarly, sustained and marked γ-H2AX levels were 
also noticed with combined verteporfin and radiation, 
even though these agents used alone at low dose only 
led to baseline or minimal γ-H2AX induction (Figure 
6C and 6D). Furthermore, consistent with a recent study 
Figure 4: (A) Clonogenic assay: The effects of siRNA-mediated YAP1 knockdown on radiation in PC9 lung cancer cells. 
(B) Clonogenic assay: The effects of siRNA-mediated YAP1 knockdown on radiation in HCC827 lung cancer cells. (C) Clonogenic assay: 
The effects of siRNA-mediated YAP1 knockdown on radiation in H157 lung cancer cells. Control: Non-targeted siRNA. XRT: radiation. 
∆ indicates that there is a synergistic effect between radiation and siRNA-mediated YAP1 knockdown (CI < 1). * = P < 0.05.
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Figure 5: (A) Representative YAP1 IHC staining with tissue microarrays constructed with 124 surgically resected non-small cell lung 
tumors. (1). normal lung. (2). EGFR/KRAS wild type NSCLC. WT: Wild type. (3). EGFR mutated NSCLC. (4). KRAS mutated NSCLC. 
(B) Clonogenic assay: The effects of siRNA -mediated YAP1 knockdown on erlotinib response in PC9 lung cancer cells. (C) Clonogenic 
assay: The effects of siRNA-mediated YAP1 knockdown on erlotinib activity in HCC827 lung cancer cells. Control: Non-targeted siRNA. 
∆ indicates that there is a synergistic effect between erlotinib and siRNA-mediated YAP1 knockdown (CI < 1). * = P < 0.05. 
Table 2: YAP1 IHC staining with tissue microarrays constructed with 124 surgically removed 
tissues
Positive nuclear 
YAP1 n (%)
Positive cytoplasmic 
YAP1 n (%)
Total positive 
YAP1 
n (%)
Average H score
of nuclear YAP1
All cases (n = 124) 58 (47%) 46 (37%) 95 (77%) 32
Histology
Adeno (n = 74) 37 (50%) 32 (43%) 64 (86%) 34
Squamous (n = 22) 13 (59%) 6 (27%) 16 (73%) 41
Large cell (n = 19) 6 (32%) 5 (26%) 11 (53%) 20
Other (n = 9) 2 (22%) 3 (33%) 5 (56%) 23
Mutation status
EGFR mutated (n = 16) 10 (63%) 7 (44%) 15 (94%) 47
KRAS mutated (n = 23) 15 (65%) 7 (30%) 20 (87%) 51
EGFR/KRAS wild type (n = 37) 16 (43%) 17 (46%) 21 (57%) 19
Positive cases were defined as samples with positive YAP1 staining (either cytoplasmic or nuclear YAP1 or both). In some 
cases, there was both nuclear and cytoplasmic YAP1 staining. The semi-quantitative H-score was determined as the sum 
of the percentage of staining (proportion score) multiplied by an ordinal value corresponding to staining intensity in the 
specimen (0 = none, 1 = weak, 2 = moderate, 3 = strong).
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in esophageal cancer [31], verteporfin diminished both 
total and phospho-YAP1 levels and EGFR expression, 
both alone and in combination with cisplatin or erlotinib 
or radiation treatment. Thus, verteporfin can influence 
EGFR signaling by down-regulating EGFR expression. 
Similar effects of verteporfin on another NSCLC cell line, 
HCC827 were also observed (data not shown). These data 
indicate that verteporfin can overcome resistance and 
sensitize NSCLC cells to cisplatin and radiation by at least 
two means: increasing levels of DSBs (more γ-H2AX) and 
decreasing expression of YAP1.
DISCUSSION
Platinum-based chemotherapy and chemoradiotherapy 
are the mainstay of the treatment paradigms for stage III/
IV NSCLC. Nevertheless, platinum and radioresistance 
remain pressing clinical problems. The underlying 
Figure 6: (A) Western blotting: The effects of verteporfin and dasatinib on YAP1 phosphorylation in PC9 cells. (B). MTS assay: The 
effects of verteporfin on cytotoxicities of cisplatin, XRT and erlotinib in PC9 lung cancer cells. Con: Vehicle DMSO control. XRT: radiation. 
∆ indicates that there is a synergistic effect between verteporfin and cisplatin, XRT and erlotinib (CI < 1). * = P < 0.05. (C) Western 
blotting: The effects of verteporfin and cisplatin (first 7 lanes) on YAP1 and γ-H2AX in PC9 cells. The last two lanes indicated the effects 
of verteporfin and erlotinib on YAP1 and γ-H2AX. (D) Western blotting: The effects of verteporfin and XRT on YAP1 and γ-H2AX in PC9 
cells. p-YAP1: phosphos-YAP1; t-YAP1: total-YAP1. 
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mechanisms are likely multi-factorial and have remained 
largely elusive. In the present study, we performed a 
genome-wide high throughput RNAi screen to search for 
novel synergistic targets the modulation of which could 
influence platinum sensitivity in lung cancer cells. We 
first identified YAP1 as a potential lead candidate to affect 
platinum sensitivity. YAP1 shRNAs were significantly 
depleted at 80 fold in the cisplatin RNAi screen. We 
then showed that both genetic (shRNA or siRNA) and 
pharmacological YAP1 blockade (verteporfin) improved 
cisplatin activity in lung cancer cells. Additionally, YAP1 
inhibition also synergized with radiation and the EGFR 
TKI, erlotinib. By targeting YAP1 signaling, verteporfin 
potentiated cisplatin and radiation-related DSBs and 
decreased expression of YAP1 and EGFR. Thus, our 
data suggests that YAP1 may be a common modulator of 
resistance mechanisms to platinum, radiation and EGFR-
targeted therapies in lung cancer. 
As a transcriptional coactivator, YAP1 is the 
downstream effector of the Hippo signaling pathway 
which is an essential regulator of organ size and tumor 
growth by modulating cell proliferation and apoptosis 
[32]. Culminating evidence suggest that YAP1 is involved 
in the modulation of cancer cell proliferation, self-
renewal of cancer stem cells and initiation of migration 
and metastasis [32, 33]. YAP1 expression has been 
suggested as a negative prognostic factor for lung cancer 
survival [26]. Under nonproliferating conditions, YAP1 
is phosphorylated and retained in the cytoplasm. Upon 
activation, YAP1 accumulates in the nucleus, and then 
associates with transcription factors, such as TEAD, 
to regulate the expression of genes that promote cell 
proliferation [32, 34, 35]. Our study showed that total 
YAP1 was expressed in 75% and the active form of 
YAP1, nuclear YAP1 was expressed in 48% of primary 
lung cancer specimens which is in line with previous 
report that YAP1 was expressed in 66% of cases and is 
found to be present predominantly in nucleus [26]. Our 
data also demonstrated that EGFR mutated or KRAS 
mutated lung cancers are associated with higher nuclear 
YAP1 expression in comparison to EGFR/KRAS wild 
type tumors. A recent study identified YAP1 as essential 
KRAS effector in the development of pancreatic ductal 
adenocarcinoma [36]. The results also corroborate prior 
findings suggestive of YAP1 expression to be regulated by 
oncogenic EGFR/KRAS signaling [28] and higher YAP1 
expression in tumors with EGFR mutations [29]. 
Moreover, YAP1 has been implicated in the 
modulation of drug sensitivities. For instance, YAP1 was 
shown to affect activities of cisplatin and EGFR inhibitors 
in ovarian cancer cells [27]. In the context of radiotherapy, 
YAP1 expression was predictive of radio-resistance in 
patients with head and neck cancer [37]. YAP1 has also 
been indicated in mediating resistance to anti-tubulin 
drugs, such as paclitaxel, in a Hippo-independent manner 
[38]. A recent study utilizing genetic screen further 
identified YAP1 as a resistance mechanism to RAF- and 
MEK-targeted therapies [17]. In accordance with previous 
findings, YAP1 was identified in our RNAi screen as a 
potential synergistic target for cisplatin. YAP1 knockdown 
potentiated the effects of cisplatin, and also the activities 
of radiation. Both cisplatin and radiation can lead to DNA 
damage with accumulation of DNA double strand breaks. 
Our study showed that the combination of verteporfin 
(YAP1 inhibitor) along with either cisplatin or radiation 
led to persistent γ-H2AX formation (marker for DNA 
double strand breaks) which is suggestive of continuous 
and unrepaired DNA damages caused by the combination. 
Thus, down-regulation of YAP1 can sensitize cells to DNA 
damaging agents.
Several studies indicated that pharmacological 
YAP1 inhibitors including verteporfin could suppress 
tumor growth or sensitize tumor cells to cytotoxics 
in a variety of tumor types, such as esophageal cancer, 
rhabdomyosarcoma, ovarian cancer and bladder cancer 
[19, 31, 39, 40]. Our data also indicate that YAP1-targeted 
therapy, verteporfin, diminished EGFR expression and 
was associated with better erlotinib cytotoxicity. The 
interplay between YAP1 and EGFR signaling was noted 
previously where EGFR activation induced YAP1 gene 
expression in a study of hepatocellular carcinoma [41], 
while YAP1 induced EGFR expression in another report 
[31]. Furthermore, a study indicated that the expression 
of cytoplasmic YAP1, which is the inactive form, was 
associated with longer-progression free survival and 
overall survival in EGFR-TKI-treated lung cancer patients 
with EGFR mutations [42]. Thereby, YAP1 blocking 
agents may also help to improve EGFR-targeted therapy. 
In summary, the present study provides evidence 
to identify YAP1 as a key and actionable determinant 
of sensitivities to platinum, radiation and erlotinib in 
lung cancer cells. We have shown that YAP1 blockade 
could sensitize lung cancer cells to cisplatin, radiation 
and erlotinib. This observation may have very important 
clinical implications as it sets up the foundation to utilize 
YAP1-targeted modalities in combination with other 
cancer therapies to achieve better therapeutic outcomes, 
especially in YAP1-positive lung cancers. Future 
mechanistic studies are certainly needed to demonstrate 
how exactly YAP1 functions as a common determinant 
modifying such diverse resistance mechanisms.
MATERIALS AND METHODS
Cell lines and material
The following NSCLC cell lines were obtained 
from American Type Tissue Collection (Manassas, VA): 
HCC827, H23, H157, H441, A549 and NHBE (normal 
human bronchial epithelial cells). PC9 cells were a gift 
from Dr. Susumu Kobayashi, Harvard Medical School, 
Boston, MA. Lung cancer cells were grown in RPMI 
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1640 supplemented with 10% FBS and 1x Antibiotic/
Antimycotic (Invitrogen, Carlsbad, CA) and were in 
the logarithmic growth phase at the initiation of all 
experiments. Verteporfin and Dasatinib (BMS-354825) 
were obtained from Selleck Chemicals (Houston, TX); 
Verteporfin is a photosensitizer, thus we conducted 
all experiments involving verteporfin in the darkness. 
The cell cultures with verteporfin were protected from 
ambient light. Cisplatin was obtained from Sigma-Aldrich 
(St. Louis, MO).
High throughput RNAi screen
As previously described [14–17] (Figure 1), we 
first transfected lung cancer cells (PC9) with an shRNA 
viral library containing 58,493 shRNA-mirs in a pooled 
format at a multiplicity of infection of one (MOI = 1). 
Cells were then treated for 14 days with DMSO as vehicle 
control vs. cisplatin (1 µM). The transduced cells were 
plated in triplicates under each experimental condition. 
Subsequently, genomic DNA was extracted, shRNAs were 
amplified, and next generation sequencing was performed 
at the Columbia University Genomic Center to determine 
the identities of shRNAs. As previously published [14, 17, 
18], we utilized a rigorous set of criteria and procedures 
for analyzing the derived data, using the Bioconductor 
and Extraction of Differential Gene Expression libraries 
in R program. Correlation between biological replicates 
was calculated. The genes from the initial positive “hits” 
screen were ranked based on the following criteria: 1. 
the presence of multiple shRNAs targeting the same 
gene; 2. the strength of the phenotype (fold change in 
representation). Given that a large number of hits on the 
primary screen were statistically significant (P < 0.05), we 
further classified these candidates based on: 1. 50-fold or 
greater depletion of corresponding shRNA (~top 3% of 
the primary hits with P < 0.01); 2. established expression 
in lung cancer with known function in carcinogenesis or 
chemotherapy resistance.
Immunoblotting and antibodies
Proteins were separated by 10% SDS-PAGE gel 
and transferred onto PVDF membranes (Bio-Rad) for 
Western blot analysis as described previously [19]. The 
antibody against YAP1 (H-125) was purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA). Antibodies against 
Phospho-YAP1 (Ser127), Cleaved PARP (Asp214), 
tubulin and Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) were purchased from Cell Signaling 
Technology (Boston, MA). Antibody against phosphor-
Histone H2AX (Ser139) was purchased from Millipore 
(Temecula, CA).
Immunohistochemistry
As previously described [19], formalin-fixed primary 
lung tumor tissue sections were deparaffinized followed by 
antigen retrieval treatment with sodium citrate (10 mM, pH 
6.0). Endogenous peroxidase activity was blocked by Dako 
peroxidase blocking reagent (Dako Corporation, Carpinteria, 
CA). YAP1 (H125) antibody was used at a dilution of 
1:1000 (optimal dilution for overnight incubation) at room 
temperature. Then DakoCytomation LSAB 2 system-HRP 
(Dako Corporation, Carpinteria, CA) was used by adding 
biotinylated link universal and streptavidin-HRP followed 
by DAB chromogen (Dako Corporation, Carpinteria, CA) 
and hematoxylin nuclear counterstaining. The expression 
of YAP1 was evaluated by using immunohistochemistry 
(IHC) in FFPE patients’ specimens by two independent 
investigators and its immunohistochemical semi-
quantitation was performed using the H-score. Positive 
cases were defined as samples with positive YAP1 staining 
(either cytoplasmic or nuclear YAP1 or both). The H-score 
was determined as the percentage of staining (proportion 
score) multiplied by an ordinal value corresponding to 
the maximum intensity level in the specimen (0 = none, 
1 = weak, 2 = moderate, 3 = strong). 
Drug combination studies with clonogenic 
survival assay
Clonogenic survival was assayed as previously 
described [20]. Logarithmically growing cells were plated 
in triplicate in 6-well tissue culture dishes containing 
media alone (200 cells per well) or media supplemented 
with drugs (including radiation) (500 cells per well). The 
plating efficiency (PE) was around 50% for untreated 
controls. Cisplatin and erlotinib were added for 3 days [5]. 
After 7–14 days, colonies were fixed with 70% EtOH and 
stained with 0.5% crystal violet. Surviving colonies were 
defined as colonies containing > 50 cells. Survival was 
expressed as the relative plating efficiency as compared 
to control cells. The Bliss Model was used to calculate the 
combination index (CI) and to evaluate the effects of drug 
combinations [21]. f1, f2 and f12 represents the effects 
from single drug 1, single drug 2 and the drug combination 
of drugs 1 & 2. The Bliss combination index (CI Bliss) = (f1 
+ f2 – f1 × f2)/f12. The drug-drug interactions (or drug –
YAP1 knockdown interaction) were defined as synergism 
if CI < 1, antagonism if CI > 1, otherwise additive. CIs 
were also checked by Calcusyn software (Biosoft) based 
on the method of Chou and Talalay [22]. Similar CI trends 
were observed with both methods. 
MTS cell growth assay
Lung cancer cells were seeded at a density of 3000 
cells (or 1500 cells for siRNA experiments) per well in 
96-well plates in RPMI 1640 containing 10% FBS on day 
0. Increasing concentrations of cisplatin (0.1 µM, 1 µM) 
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or radiation (2 Gy, 4 Gy) or erlotinib (1 nM, 5 nM) were 
introduced on day 1 with or without YAP1 inhibition 
(either genetically or pharmacologically with verteporfin) 
[23]. The cells were incubated in the presence of drug 
treatment for 3 days. Viable cell numbers on day 4 were 
determined using the MTS assay kit according to the 
manufacturer’s protocol (Promega, Madison, WI). Each 
assay consisted of three replicate wells. 
Small interfering RNA (siRNA) knockdown
Knockdown of YAP1 was performed using siRNA 
pools targeting YAP1 (ON-TARGET plus SMARTpool) 
purchased from Dharmacon RNAi Technologies (Thermo, 
Rockford, IL). SiGENOME Nontargeting siRNA Pools 
served as negative control. Introduction of siRNA 
(300 nM) was performed with DharmaFect1 transfection 
reagent according to the manufacturer’s instructions 
(Thermo). Levels of YAP1 knockdown at different time 
points were assessed by immunoblot analysis from pools 
of transfected cells.
Inducible shRNA knockdown
The Thermo Scientific Open Biosystems Expression 
Arrest TRIPZ Lentiviral shRNAmir was used for inducible 
shRNA knockdown of YAP1 per manufacturer’s manual 
(TRIPZ Human YAP1 shRNA, Thermo Fisher Scientific, 
PA, USA). Individual TRIPZ Human YAP1 shRNA 
(Clone ID: V2THS_247011) was used as shRNA #1, 
TRIPZ Human YAP1 shRNA (Clone ID: V2THS_65508) 
was used as shRNA #2 and TRIPZ Human YAP1 shRNA 
(Clone ID: V2THS_65509) was used as shRNA#3. 
Doxycycline induction led to efficient knockdown of 
YAP1 as assessed by Western blotting. Pooled NSCLC 
cells with inducible shRNA-YAP1 were only utilized 
within a month following transduction. 
Statistics
All data are expressed as means ± SD from at least 
triplicate experiments. Statistical analysis of cell lines was 
performed by one- or two-way ANOVA, as appropriate 
using Statistica 6.0 (StatSoft, Tulsa, OK). YAP1 
expression levels by IHC were compared between groups 
defined by mutation status and histology with the Kruskal-
Wallis test. A two-sided p-value < 0.05 was considered 
statistically significant. 
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